All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-08-23T08:16:09.000Z

Phase II study of cladribine plus low-dose cytarabine alternating with decitabine in elderly patients with acute myeloid leukemia

Aug 23, 2018
Share:

Bookmark this article

In the August 2018 issue of Lancet Haematology, a group of researchers from the MD Anderson Cancer Center, Houston, TX, published data from an open-label phase II study (NCT01515527), which is assessing a new low-intensity regimen of cladribine plus low-dose cytarabine (LDAC) alternating with decitabine in elderly or unfit patients with newly diagnosed acute myeloid leukemia (AML).

One hundred and eighteen elderly or unfit patients (median age = 69 years, range 65–73) with newly diagnosed AML were enrolled sequentially into this phase II study. Patients received cladribine plus LDAC for two 28-day cycles alternating with decitabine for two 28-day cycles for up to 18 cycles. For induction, patients received cladribine (5 mg/m2 on days 1–5) plus LDAC (20 mg subcutaneously on days 1–10 [cycle A]). Patients who achieved remission then received a consolidation therapy consisting of cladribine (5 mg/m2 on days 1–3) and LDAC (20 mg subcutaneously on days 1–10) alternating with decitabine (20 mg/m2 intravenously on days 1–5 [cycle B]). The primary objective of the study was disease-free survival (DFS).

Key findings:

Efficacy

  • Median follow-up: 37.2 months
  • Objective response: 68% (80/118)
    • Complete response (CR): 58% (69/118)
    • CR with incomplete count recovery: 9% (11/118)
  • Median duration of remission in responders: 14.7 months (7.0–not reached)
  • Median overall survival in all patients: 13.8 months (6.9–28.6 months)
  • Median OS in responders and non-responders: 16.2 vs 4.7 months
  • Median DFS in all patients: 10.8 months (5.4–25.9 months)

Minimal residual disease (MRD)

  • MRD was performed at the time of response assessment (at day 30 and 60) in 71 patients
  • At day 30, 27 (52%) of the 52 patients who achieved objective response with MRD data were MRD negative
  • At day 60, 13 (50%) of the 26 patients who achieved objective response with MRD data were MRD negative
  • MRD positivity at day 60 associated with inferior OS

Safety

  • The most common study-related adverse events were elevated total bilirubin, rash, and nausea
  • Four-week mortality rate: 1% (1/118)
  • 8-week mortality rate: 7% (8/118)

In summary, this new low-intensity regimen of cladribine plus LDAC alternating with decitabine was well tolerated and effective in elderly or unfit patients with AML. Additionally, “response to therapy was associated with longer survival”.

Key limitations of this study include the risk of selection bias, the inclusion criteria were not flexible enough to allow a broad enrollment of patients and lack of information about subsequent treatment for patients whose AML relapsed during the study.

  1. Kadia T. M. et al. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Aug 13. DOI: 10.1016/S2352-3026(18)30132-7. [Epub ahead of print].

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox